BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 7.1% in October

BioAtla, Inc. (NASDAQ:BCAB) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 4,870,000 shares, a decrease of 7.1% from the October 15th total of 5,240,000 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is currently 4.0 days.

Wall Street Analyst Weigh In

BCAB has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of BioAtla in a research report on Monday, September 16th. HC Wainwright lowered BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BCAB. Vontobel Holding Ltd. acquired a new stake in shares of BioAtla during the 3rd quarter valued at about $28,000. Ground Swell Capital LLC bought a new position in BioAtla during the second quarter valued at approximately $33,000. Valmark Advisers Inc. acquired a new stake in BioAtla in the second quarter valued at approximately $34,000. Rinkey Investments bought a new stake in BioAtla in the second quarter worth approximately $35,000. Finally, Chicago Partners Investment Group LLC acquired a new position in shares of BioAtla during the 3rd quarter worth $44,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Stock Performance

Shares of BCAB opened at $1.56 on Monday. The company has a market capitalization of $75.43 million, a PE ratio of -0.92 and a beta of 1.03. The company’s 50 day moving average price is $1.91 and its 200 day moving average price is $1.86. BioAtla has a 52 week low of $1.14 and a 52 week high of $4.02.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.12. The company had revenue of $11.00 million for the quarter. During the same quarter in the prior year, the company posted ($0.70) EPS. On average, equities analysts forecast that BioAtla will post -1.49 earnings per share for the current fiscal year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.